This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

GO-REVEAL 5-year long-term extension study

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) 1

GO-REVEAL Study
Prescribing Information

The GO-REVEAL 5-year long-term extension study assesses golimumab’s long-term efficacy and safety in psoriatic arthritis (PsA)1.

Read the study from the EULAR Journal

By study design, randomisation of weight; patients in the long-term extension may have switched between 50mg and 100mg SIMPONI doses at the discretion of the study physician.

Refer to SIMPONI prescribing information for full licensed weight based dosing.

References:

  1. Kavanaugh A et al. Ann Rheum Dis 2014; 73: 1689-1694

More information about SIMPONI® (golimumab):